rofecoxib
Meaning of rofecoxib: A drug designed to fix one problem that created a larger one, and much of the reason anti-inflammatories now carry heart warnings.
Definition of rofecoxib
Rofecoxib is a painkiller of the coxib group, withdrawn worldwide by its maker after trials showed it raised the risk of heart attack and stroke. It blocked COX-2, one of the two enzymes producing the messengers behind pain, fever and swelling, while leaving the other enzyme alone. That design was intended to relieve arthritis pain without stripping the stomach of its protection.
What was it designed to solve?
Ordinary anti-inflammatory painkillers block both forms of the enzyme. One form runs quietly in the background, keeping the stomach lining protected and platelets able to clot. The other is switched on at sites of injury and inflammation. Blocking both relieves pain but removes the stomach's defenses, and ulcers and serious bleeding follow often enough to cause many hospital admissions each year. A drug hitting only the inflammation enzyme promised the same relief without that cost, and on that narrow measure it delivered.
Why did it cause harm?
The balance it disturbed lay in the blood vessels. Their lining uses the inflammation enzyme to make a messenger that widens vessels and discourages platelets from clumping. Platelets themselves use the other enzyme to make a messenger doing precisely the opposite. Removing one side while leaving the other untouched tilted the system toward clotting, and the drug also caused fluid retention and pushed blood pressure up. The signal emerged clearly in a trial testing whether it could stop bowel polyps returning, and the drug was pulled from markets worldwide rather than from one country alone.
What came of it?
| Aspect | Where it stands |
|---|---|
| Other coxibs | Some remain available, carrying cardiovascular warnings |
| Older painkillers | Warnings were extended to the nonselective drugs too |
| Cancer prevention | Still studied, with the risk now weighed against benefit |
| Drug surveillance | Prompted closer monitoring of drugs after approval |
The old listing calling it an antiangiogenesis agent reflects a research program rather than what the drug was. Laboratory work showed that blocking this enzyme can slow the growth of new blood vessels, and that reasoning drove interest in cancer prevention, but the drug was a nonsteroidal anti-inflammatory drug and was never established as anything else.
Also known as
Used in a sentence
The medication history noted rofecoxib use before the drug was withdrawn.
Good to know
The withdrawal applied to markets worldwide rather than to the United States alone, and the harm followed from selective blockade of a single enzyme, which left the clot-promoting side of the same system intact.